Interpretation of genotype and pharmacokinetics for resistance to fosamprenavir-ritonavir-based regimens in antiretroviral-experienced patients

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1473-1480

  Pellegrin, Isabelle ^a,b   Breilh, Dominique ^a   Coureau, Gaelle ^a   Boucher, Sébastien ^a   Neau, Didier ^a   Merel, Patrick ^a   Lacoste, Denis ^a   Fleury, Hervé ^a   Saux, Marie Claude ^a   Pellegrin, Jean Luc ^a   Lazaro, Estibaliz ^a   Dabis, François ^a   Thiébaut, Rodolphe ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE; AMPRENAVIR PHOSPHATE; ARGININE; ATAZANAVIR; CD4 ANTIGEN; CYSTEINE; EMTRICITABINE; ENFUVIRTIDE; GLUTAMIC ACID; ISOLEUCINE; LAMIVUDINE; LEUCINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LYSINE; METHIONINE; PHENYLALANINE; PROLINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL; VALINE; VIRUS ENZYME; ZIDOVUDINE;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; FRANCE; GENE SEQUENCE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM; SEQUENCE ANALYSIS; VIRUS LOAD; VIRUS MUTATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD;

EID: 34247147510     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00481-06     Document Type: Article

References (44)

1. Boffito, M., L. Dickinson, A. Hill, D. Back, G. Moyle, M. Nelson, C. Higg, C. Fletcher, B. Gazzard, and A. Pozniak. 2004. Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 37:1376-1384.
2. Breilh, D., I. Pellegrin, A. Rouzes, K. Berthoin, F. Xuereb, H. Budzinski, M. Munck, H. J. A. Fleury, M. C. Saux, and J. L. Pellegrin. 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305-1310.
3. Breilh, D., I. Pellegrin, G. Coureau, J. B. Gordien, D. Lacoste, J. L. Pellegrin, D. Neau, M. Dupon, H. J. A. Fleury, M. C. Saux, and the GECSA. 2005. Switch to fosamprenavir/ritonavir (FPV/r) based HAART in experienced patients with virological failure on HAART (ZEPHIR study): impact of pharmacokinetics on response at M3. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. H-1903.
4. Brun-Vézinet, F., D. Costagliola, M. Ait Khaled, V. Calvez, F. Clavel, C. Clotet, R. Haubrich, D. Kempf, M. King, D. Kuritzkes, R Lanier, M. Miller, V. Miller, A. Phillips, D. Pillay, J. Schapiro, J. Scott, R. Shafer, M. Zazzi, A. Zolopa, and V. de Gruttola. 2004. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir. Ther. 9:465-478.
5. Ceccherini-Silberstein, F., F. Erba, F. Gago, A. Bertoli, F. Forbici, M. C. Bellocchi, C. Gori, R. D'Arrigo, L. Marcon, C. Balotta, A. Antinori, A. D. Monforte, and C. F. Perno. 2004. Identification of the minimal conserved structure of HIV-1 protease in the presence or absence of drug pressure. AIDS 18:11-19.
6. Decker, C. J., L. M. Laitinen, G. W. Bridson, S. A. Raybuck, R. D. Tung, and P. R. Chaturvedi. 1998. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J. Pharm. Sci. 87:803-807.
7. DeJesus, E., A. Lamarca, M. Sension, C. Beltran, and P. Yeni. 2003. The context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results) 10th Conf. Retrovir. Opportun. Infect., abstr. 178.
8. Delfraissy, J. F. 2004. Prise en charge thérapeutique des personnes infectées par le VIH, recommandations du groupe d'experts. Editions Flammarion: Medecine-Sciences, Paris, France.
9. Descamps, D., B. Masquelier, J. P. Mamet, V. Calvez, A. Ruffault, F. Telles, A. Goetschel, P. M. Girard, F. Brun-Vezinet, and D. Costagliola. 2001. A genotypic sensitivity score for amprenavir based on genotype at baseline and virological response. Antivir. Ther. 6(Suppl. 1):103.
10. Duval, X., C. Lamotte, E. Race, D. Descamps, F. Damond, F. Clavel, C. Leport, G. Peytavin, and J. L. Vilde. 2002. Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir. Antimicrob. Agents Chemother. 46:570-574.
11. Elston, R., S. White, P. Yates, F. Xu, N. Richards, S. Sharp, M. B. Wire, and M. Tisdale. 2004. A genotypic inhibitory quotient (GIQ) for fosamprenavir/ rtv (908/r). Antivir. Ther. 9:S129.
12. Gathe, J. C., P. Ive, R. Wood, D. Schurmannd, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18:1529-1537.
13. Gonzalez de Requena, D., O. Gallego, L. Valer, I. Jimenez-Nacher, and V. Soriano. 2004. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res. Hum. Retrovir. 20:275-278.
14. Goujard, C., I. Vincent, J. L. Meynard, N. Choudet, D. Bollens, C. Rousseau, D. Demarles, C. Gillotin, R. Bidault, and A. M. Taburet. 2003. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 47:118-123.
15. Huang, L., S. A. Wring, J. L. Woolley, K. R. Brouwer, C. Serabjit-Singh, and J. W. Polli. 2001. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab. Dispos. 29:754-760.
16. Jelliffe, R., A. Schumitzky, and M. Van Guilder. 2000. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods. Ther. Drug Monit. 22:354-365.
17. Johnson, V. A., F. Brun-Vezinet, B. Clotet, B. Conway, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, A. Telenti, and D. D. Richman. 2005. Drug resistance mutations in HIV-1: 2005. Top. HIV Med. 13:125-131.
18. Kearney, B. P., A. Mathias, A. Mittan, J. Sayre, R. Ebrahimi, and A. K. Cheng. 2006. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 43:278-283.
19. Marcelin, A. G., C. Dalban, G. Peytavin, C. Lamotte, R. Agher, C. Delaugerre, M. Wirden, F. Conan, S. Dantin, C. Katlama, D. Costagliola, and V. Calvez. 2004. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 48:4687-4692.
20. Marcelin, A. G., C. Lamotte, C. Delaugerre, N. Ktorza, H. Ait Mohand, R. Cacace, M. Bonmarchand, M. Wirden, A. Simon, P. Bossi, F. Bricaire, D. Costagliola, C. Katlama, G. Peytavin, V. Calvez, and the Genophar Study Group. 2003. Genotypic inhibitory quotient as predictor of virological re-sponse to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 47:594-600.
21. Marcelin, A. G., D. Affolabi, C. Lamotte, H. Ait Mohand, C. Delaugerre, M. Wirden, D. Voujon, P. Bossi, N. Ktorza, F. Bricaire, D. Costagliola, C. Katlama, G. Peytavin, and V. Calvez. 2004. Resistance profiles observed in virological failures after 24 weeks of amprcnavir/ritonavir containing regimen in protease inhibitor experienced patients. J. Med. Virol. 74:16-20.
22. Mazumdar, M., A. Smith, and J. Bacik. 2003. Methods for categorizing a prognostic variable in a multivariable setting. Stat. Med. 22:559-571.
23. Parikh, U., C. Calef, B. A. Larder, R. Schinazi, and J. W. Mellors. 2002. Mutations in retroviral genes associated with drug resistance, p. 95-183. In C. Kuiken, B. Foley, E. Freed, B. Hahn, B. Korber, P. Marx, F. McCutchan, and J. W. Mellors (ed.), HIV sequence compendium 2002. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM.
24. Parkin, N. T., C. Chappey, and C. J. Petropoulos. 2003. Improving lopinavir genotype algorithm through phenotype correlations: "novel" mutation patterns and amprenavir cross-resistance. AIDS 17:955-961.
25. Parks, D. A., H. C. Jennings, C. W. Taylor, and E. D. Acosta. 2005. Pharmacokinetics of fosamprenavir, ritonavir, tenofovir and emtricitabine administered once daily in treament naive HIV-infected subjects. 3rd Int. AIDS Soc. Conf., abstr. TuPeLB3.1B.01.23001.
26. Pellegrin, I., P. Merel, I. Garrigue, A. Caumont, M. H. Schrive, V. Birac, P. Bonot, and H. J. A. Fleury. 2001. Comparison of capillary electrophoresis sequencing with the new CEQ32000 System (Beckman Coulter Inc.) to conventional gel based systems for HIV-1 drug resistance analysis. J. Virol. Methods 98:9-16.
27. Pellegrin, I., G. Coureau, D. Neau, D. Lacoste, E. Lazaro, H. J. A. Fleury, D. Breilh, and the GECSA. 2005. Impact of protease drug mutations and pharmacokinetics on virological response to fosamprenavir/r-based HAART in antiretroviral-experienced patients (Zephir study). 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. H-1059.
28. Pellegrin, I., D. Breilh, V. Birac, M. Denayrolles, P. Mercie, A. Trylesinski, D. Neau, M. C. Saux, H. J. A. Fleury, and J. L. Pellegrin. 2001. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/ saquinavir-containing regimens. Ther. Drug Monit. 23:332-340.
29. Pellegrin, I., D. Breilh, F. Montestruc, A. Caumont, I. Garrigue, P. Morlat, C. Le Camus, M. C. Saux, H. J. A. Fleury, and J. L. Pellegrin. 2002. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16:1331-1340.
30. Pellegrin, I., D. Breilh, J. M. Ragnaud, S. Boucher, D. Neau, H. J. A. Fleury, M. H. Schrive, M. C. Saux, J. L. Pellegrin, E. Lazaro, and M. Vray. 2006. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar Study). Antivir. Ther. 11:421-429.
31. Peytavin, G., A. G. Marcelin, A. Rouault, R. Agher, D. Descamps, V. Calvez, and C. Katlama. 2005. Plasma concentrations of amprenavir, ritonavir and tenofovir in HIV-infected patients treated with fosamprenavir/ritonavir (700/ 100 mg BID) and tenofovir (300 mg QD) containing regimen. 6th Int. Workshop Clin. Pharmacology HIV Ther., abstr. 2.25.
32. Rodriguez-French, A., J. Boghossian, G. E. Gray, J. P. Nadler, A. R. Quinones, G. E. Sepulveda, J. M. Millard, and P. G. Wannamaker. 2004. The NEAT study: a 48-week open label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1 infected patients. J. Acquir. Immune Defic. Syndr. 35:22-32.
33. Sadler, B. M., P. J. Piliero, S. L. Preston, P. P. Lloyd, Y. Lou, and D. S. Stein. 2001. Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers. AIDS 15:1009-1018.
34. Sale, M., B. M. Sadler, and D. S. Stein. 2002. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob. Agents Chemother. 46:746-754.
35. Shurmann, D., R. Elston, F. Xu, N. Kleinkauf, T. Wunsche, and N. Suttorp. 2006. Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. AIDS 2:138-140.
36. Svicher, V., F. Ceccherini-Silberstein, M. Erba, M. Santoro, C. Gori, M. C. Bellocchi, S. Giannella, M. P. Trotta, A. Monforte, A. Antinori, and C. F. Perno. 2005. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob. Agents Chemother. 49:2015-2025.
37. Taburet, A. M., C. Piketty, C. Chazallon, I. Vincent, L. Gérard, V. Calvez, F. Clavel, J. P. Aboulker, P. M. Girard, and the ANRS Protocol 107 Puzzle 2 Investigators. 2004. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48:2091-2096.
38. Thiébaut, R., P. Morlat, H. Jacqmin-Gadda, D. Neau, P. Mercié, F. Dabis, and G. Chene. 2000. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. AIDS 14:971-978.
39. Valer, L., C. De Mendoza, and V. Soriano. 2005. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J. Med. Virol. 77:460-464.
40. Vora, S., A. G. Marcelin H. Günthard, P. Flandre, H. H. Hirsch, B. Masquelier, A. Zinkernagel, G. Peytavin, V. Calvez, L. Perrin, and S. Yerly; Swiss HIV Cohort Study. 2006. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients. AIDS 20:35-40.
41. Wire, M. B., K. L. Baker, L. S. Jones, M. J. Shelton, Y. Lou, G. J. Thomas, and M. M. Berrey. 2006. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob. Agents Chemother. 50:1578-1580.
42. Wire, M. B., M. J. Shelton, and S. Studenberg. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45:137-168.
43. Wood, R., K. Aresteh, H. J. Stellbrink, E. Teofilo, F. Raffi, R. Pollard, J. Eron, J. Yeo, J. Millard, M. B. Wire, and O. J. Naderer. 2004. A 6-week randomized controlled trial to compare the tolerability, pharmacokinetics and antiviral activity of GW433908 and amprenavir in HIV-1-infected subjects. Antimicrob. Agents Chemother. 48:116-123.
44. Wu, T. D., C. A. Schiffer, M. J. Gonzales, J. Taylor, R. Kantor, S. Chou, D. Israelski, A. R. Zolopa, W. J. Fessel, and R. W. Shafer. 2003. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77:4836-4847.